Anavex Life Sciences Corp (AVXL)

[McMagyar]

Ziggy..
I understood what you meant..
did you read my whole post..
A Study is a Study..unless of course it is called an
ADAPTIVE STUDY..then everything you said holds true but
the parameters, methods and controls may all be adjusted
to what ay be hypothesixd to offer teh ost insight into a postiive outcome..
So..by allowing or changing or adapting the Monotherapy versus Aricept
we ALLOW for MORE DATA NOW..NONE of the Numbers of Patients in any grouping are going to be large enough to determine EFFICACAL DATA, but they may give us great insight into Structuring Phase 3!
What if 10 of the remaining 20 A2-73 and Aricept Patients are asked to
discontinue Aricept? You can't make them..I would not think..but you could ASK..THen our Data in 5 Months would include MOno Therapy with A2-73..

If THERE numbers went UP like the current 7 Monotherapy Numbers..and there were no ILL SIDE EFFECTS from Dropping Aricept..THEN we would have BETTER SCIENCE with which to design Phase 3..Yes?
There is no blind, no placebo..so we SEE THE DATA IN REAL TIME..ALL THE DATA ..except PK/PD..